Shanghai Rendu Biotechnology Co (SHSE:688193) Piotroski F-Score: 6 (As of Jul. 23, 2026) — 20% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688193 Shanghai Rendu Biotechnology Co Ltd SHSE:688193
61 GF Score
Price ¥41.00
GF Value ¥35.09
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Shanghai Rendu Biotechnology Co Piotroski F-Score?

Shanghai Rendu Biotechnology Co SHSE:688193 -2.50% 61 Piotroski F-Score is 6 as of Jul. 23, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates SHSE:688193 with a GF Score™ of 61/100 and a GF Value™ of ¥35.09 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Shanghai Rendu Biotechnology Co ranks better than 79.9% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Rendu Biotechnology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanghai Rendu Biotechnology Co's Piotroski F-Score or its related term are showing as below:

SHSE:688193' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 7
Current: 6

During the past 8 years, the highest Piotroski F-Score of Shanghai Rendu Biotechnology Co was 7. The lowest was 1. And the median was 5.

Shanghai Rendu Biotechnology Co  (SHSE:688193) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai Rendu Biotechnology Co Piotroski F-Score Related Terms


Shanghai Rendu Biotechnology Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shanghai Rendu Biotechnology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Rendu Biotechnology Co Piotroski F-Score Chart

Shanghai Rendu Biotechnology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A 2.00 7.00 5.00 6.00

Shanghai Rendu Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 3.00 6.00 6.00

SHSE:688193 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Shanghai Rendu Biotechnology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Rendu Biotechnology Co Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Rendu Biotechnology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Rendu Biotechnology Co's Piotroski F-Score falls into.


SHSE:688193
61GF Score
Shanghai Rendu Biotechnology Co Ltd SHSE:688193
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 0.817 + 4.976 + 3.074 + 4.995 = ¥13.9 Mil.
Cash Flow from Operations was 1.803 + 6.801 + 16.648 + -10.126 = ¥15.1 Mil.
Revenue was 40.558 + 37.912 + 42.788 + 42.079 = ¥163.3 Mil.
Gross Profit was 32.364 + 29.081 + 33.738 + 32.067 = ¥127.3 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(986.629 + 984.935 + 990.177 + 990.169 + 984.023) / 5 = ¥987.1866 Mil.
Total Assets at the begining of this year (Mar25) was ¥986.6 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2.7 Mil.
Total Current Assets was ¥889.6 Mil.
Total Current Liabilities was ¥59.4 Mil.
Net Income was 0.627 + 0.34 + -12.483 + 1.221 = ¥-10.3 Mil.

Revenue was 41.865 + 43.964 + 46.708 + 40.685 = ¥173.2 Mil.
Gross Profit was 34.156 + 34.765 + 35.948 + 31.198 = ¥136.1 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1040.825 + 1021.502 + 1005.295 + 994.358 + 986.629) / 5 = ¥1009.7218 Mil.
Total Assets at the begining of last year (Mar24) was ¥1,040.8 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2.9 Mil.
Total Current Assets was ¥879.7 Mil.
Total Current Liabilities was ¥65.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Rendu Biotechnology Co's current Net Income (TTM) was 13.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Rendu Biotechnology Co's current Cash Flow from Operations (TTM) was 15.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=13.862/986.629
=0.01404986

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-10.295/1040.825
=-0.00989119

Shanghai Rendu Biotechnology Co's return on assets of this year was 0.01404986. Shanghai Rendu Biotechnology Co's return on assets of last year was -0.00989119. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai Rendu Biotechnology Co's current Net Income (TTM) was 13.9. Shanghai Rendu Biotechnology Co's current Cash Flow from Operations (TTM) was 15.1. ==> 15.1 > 13.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=2.716/987.1866
=0.00275125

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2.89/1009.7218
=0.00286217

Shanghai Rendu Biotechnology Co's gearing of this year was 0.00275125. Shanghai Rendu Biotechnology Co's gearing of last year was 0.00286217. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=889.611/59.415
=14.97283514

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=879.711/65.295
=13.47286929

Shanghai Rendu Biotechnology Co's current ratio of this year was 14.97283514. Shanghai Rendu Biotechnology Co's current ratio of last year was 13.47286929. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai Rendu Biotechnology Co's number of shares in issue this year was 41.628. Shanghai Rendu Biotechnology Co's number of shares in issue last year was 40.698. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=127.25/163.337
=0.77906414

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=136.067/173.222
=0.78550646

Shanghai Rendu Biotechnology Co's gross margin of this year was 0.77906414. Shanghai Rendu Biotechnology Co's gross margin of last year was 0.78550646. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=163.337/986.629
=0.16555058

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=173.222/1040.825
=0.16642759

Shanghai Rendu Biotechnology Co's asset turnover of this year was 0.16555058. Shanghai Rendu Biotechnology Co's asset turnover of last year was 0.16642759. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Rendu Biotechnology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Shanghai Rendu Biotechnology Co (SHSE:688193) has a Piotroski F-Score of 6 as of Jul. 23, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Rendu Biotechnology Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Shanghai Rendu Biotechnology Co's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Shanghai Rendu Biotechnology Co ranks #42 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 20.1%.
Is Shanghai Rendu Biotechnology Co's Piotroski F-Score too high?
Shanghai Rendu Biotechnology Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Shanghai Rendu Biotechnology Co's value of 6 is 20% above this industry median. Based on the distribution chart, Shanghai Rendu Biotechnology Co ranks #42 out of 209 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Rendu Biotechnology Co has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Rendu Biotechnology Co's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shanghai Rendu Biotechnology Co ranks #42 out of 209 companies for Piotroski F-Score. This places Shanghai Rendu Biotechnology Co in the top 20% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Shanghai Rendu Biotechnology Co's value of 6 is 20% above this benchmark. Historically, Shanghai Rendu Biotechnology Co's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Shanghai Rendu Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Rendu Biotechnology Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Rendu Biotechnology Co and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Rendu Biotechnology Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Rendu Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co (SHSE:688193) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥35.09, compared to a current price of ¥41.00 — trading 16.8% above its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Medical Diagnostics & Research industry median of 5.00. Shanghai Rendu Biotechnology Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shanghai Rendu Biotechnology Co (SHSE:688193), the current Piotroski F-Score is 6 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Rendu Biotechnology Co (SHSE:688193) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co stock appears to be overvalued. The current stock price of ¥41.00 is trading 16.8% above its estimated GF Value™ of ¥35.09. GuruFocus considers Shanghai Rendu Biotechnology Co to be Modestly Overvalued.

Key valuation signals for SHSE:688193:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: ¥35.09 vs. price of ¥41.00 (16.8% above fair value)
  • GF Score™: 61/100 with 2 warning signs
  • Industry Position: 20% above the Medical Diagnostics & Research median (#42 of 209)

No single metric tells the full story. See the SHSE:688193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Rendu Biotechnology Co Business Description

Address No. 528, Ruiqing Road, No. B, Building 15, East District, Zhangjiang Hi-Tech Park, Shanghai, CHN, 201201
Shanghai Rendu Biotechnology Co Ltd provides solutions for accurate diagnosis, effective prevention and control, as well as personalized diagnosis and treatment of pathogens in the areas of reproduction, respiration, digestion, blood, food, and environmental safety.
61GF Score

Get the complete analysis for SHSE:688193

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥41.00
Price
¥35.09
GF Value